Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322955 · ClinicalTrials.gov registry record · Phase 2
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
A Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, sponsored by Mark Stein.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT04322955: Recruiting Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, sponsored by Mark Stein.
NCT04322955 is a Phase 2 study of Renal Cell Carcinoma and Kidney Cancer that is actively recruiting participants, run by Mark Stein. The registered enrollment target is 48 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04322955, a Phase 2 study of Renal Cell Carcinoma and Kidney Cancer, is actively recruiting participants, sponsored by Mark Stein.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment.
Primary Outcome
The percentage of participants with a complete response following treatment. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Cabozantinib
- PROCEDURE Cytoreductive nephrectomy
Study Locations (4)
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University Wexner Medical Center - Columbus
New Jersey
- The Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
What NCT04322955 shows while recruiting
NCT04322955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04322955 reports a single indexed study location in Ohio, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT04322955 about?
NCT04322955 is a clinical study titled "CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition". The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment.
What is the current status of trial NCT04322955?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-06-22. Estimated completion is 2028-02.
What conditions does trial NCT04322955 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Kidney Cancer.
What interventions are being tested in trial NCT04322955?
The interventions under investigation include: Nivolumab (DRUG), Cabozantinib (DRUG), Cytoreductive nephrectomy (PROCEDURE).
Who is sponsoring clinical trial NCT04322955?
This trial is sponsored by Mark Stein, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04322955 being conducted?
This trial has 4 study locations across New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04322955's enrollment target sits among peer trials
48 80th of 121 higher than 41 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI